**In vitro and in vivo Characterization of BI 1823911 – a Novel KRAS\(^{G12C}\) Selective Small Molecule Inhibitor**

Fabio Savarese\(^1\), Andrea Golker\(^1\), Dorothea Rudolph\(^1\), Melanie Wurm\(^1\), Jesse Lipp\(^1\), Johannes Popow\(^1\), Marco H. Hofmann\(^1\), Herbert Arnhold\(^1\), Jörg Rinnefeld\(^2\), Francesca Trapani\(^3\), Michael Gauch\(^1\), Daniel Gerlach\(^1\), Andreas Wernigst\(^1\), Joachim Broder\(^1\), Peter Eltmeyer\(^1\), Andreas Mantoulidis\(^1\), Jason Phan\(^1\), Chris Smithhurst\(^1\), Matthias Treu\(^1\), Alex G. Waterson\(^1\), Hengyu Lu\(^1\), Annette Machado\(^1\), Joshua Daniell\(^1\), Stephen W. Fee\(^1\), Christopher P. Williams\(^1\), Timothy P. Heffernan\(^1\), Joseph R. Marszalek\(^1\), Darryl B. McCollin\(^1\), Mark Petrzon\(^1\), Norbert Kraut\(^1\) and Irene C. Weizsäger\(^1\)

\(^1\) Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
\(^2\) Boehringer Ingelheim Pharmaceuticals, Inc., West Haven, Connecticut, USA
\(^3\) Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

**Key findings and conclusions**

- BI 1823911 is a selective and potent KRAS\(^{G12C}\) inhibitor
- In vivo efficacy at 60 mg/kg is comparable to 500 mg/kg AMG 510 on MITT49B
- Combination of BI 1823911 with SOS1 inhibitor BI 174163 shows increased PO modulation and deeper anti-tumor efficacy. Further supporting data on the combination are shown in panel R1271

**Presentation at the AACR Virtual Annual Meeting 2021**

This study was funded by Boehringer Ingelheim. The authors fully disclose all financial and other relationships as mandated by the meeting and have approved the final version.